Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
7.60
-0.06 (-0.78%)
Mar 2, 2026, 2:56 PM EST - Market open
Company Description
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States.
Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Intensity Therapeutics, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Jun 30, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Lewis Bender |
Contact Details
Address: 1 Enterprise Drive, Suite 430 Shelton, Connecticut 06484-4779 United States | |
| Phone | 203 221 7381 |
| Website | intensitytherapeutics.com |
Stock Details
| Ticker Symbol | INTS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001567264 |
| CUSIP Number | 45828J202 |
| ISIN Number | US45828J2024 |
| Employer ID | 46-1488089 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Lewis H. Bender M.A., M.B.A., M.S. | Founder, President, Chief Executive Officer and Chairman of the Board |
| Joseph Talamo CPA, M.B.A. | Chief Financial Officer |
| John Wesolowski CPA, M.B.A. | Principal Accounting Officer and Controller |
| James M. Ahlers | Executive Vice President of Corporate Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 13, 2026 | 8-K | Current Report |
| Jan 23, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 5, 2025 | 8-K | Current Report |
| Dec 4, 2025 | 8-K | Current Report |
| Dec 4, 2025 | 424B5 | Filing |
| Nov 6, 2025 | 8-K | Current Report |
| Nov 6, 2025 | 10-Q | Quarterly Report |
| Nov 3, 2025 | 424B5 | Filing |
| Oct 31, 2025 | 8-K | Current Report |
| Oct 23, 2025 | 8-K | Current Report |